| # | Drug | Count |
|---|---|---|
| 0 | CANAGLIFLOZIN | 281 |
| 1 | EMPAGLIFLOZIN | 106 |
| 2 | METFORMIN | 90 |
| 3 | METFORMIN ER 500 MG | 83 |
| 4 | METFORMIN ER 750 MG | 83 |
| 5 | DAPAGLIFLOZIN | 73 |
| 6 | ADALIMUMAB | 24 |
| 7 | ASPIRIN | 24 |
| 8 | ASPIRIN 325 MG | 23 |
| 9 | ASPIRIN 81 MG | 23 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | BENZOCAINE AND LEVOMENTHOL | 1 | 0.0667 |
| 1 | BENZOCAINE, MENTHOL | 1 | 0.0435 |
| 2 | HUMAN GROWTH HORMONE | 1 | 0.0143 |
| 3 | CANAGLIFLOZIN | 281 | 0.0094 |
| 4 | ERTUGLIFLOZIN | 9 | 0.0081 |
| 5 | ZONGERTINIB | 1 | 0.0060 |
| 6 | CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 8 | 0.0044 |
| 7 | CICLOPIROX OLAMINE | 2 | 0.0042 |
| 8 | ALOGLIPTIN AND PIOGLITAZONE | 1 | 0.0040 |
| 9 | ADALIMUMAB-ADBM | 1 | 0.0037 |
| # | Drug class | Count |
|---|---|---|
| 0 | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] | 138 |
| 1 | Nonsteroidal Anti-inflammatory Drug [EPC] | 38 |
| 2 | Insulin Analog [EPC] | 36 |
| 3 | GLP-1 Receptor Agonist [EPC] | 32 |
| 4 | Tumor Necrosis Factor Blocker [EPC] | 28 |
| 5 | Corticosteroid [EPC] | 27 |
| 6 | HMG-CoA Reductase Inhibitor [EPC] | 24 |
| 7 | Platelet Aggregation Inhibitor [EPC] | 24 |
| 8 | Progestin [EPC] | 23 |
| 9 | Benzodiazepine [EPC] | 20 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] | 138 | 0.0013 |
| 1 | Guanylate Cyclase-C Agonist [EPC] | 2 | 0.0010 |
| 2 | Thyroid Hormone Receptor beta Agonist [EPC] | 1 | 0.0004 |
| 3 | Interleukin-17A Antagonist [EPC] | 14 | 0.0004 |
| 4 | Peroxisome Proliferator Receptor alpha Agonist [EPC] | 18 | 0.0003 |
| 5 | Provitamin D2 Compound [EPC] | 9 | 0.0003 |
| 6 | Calcitonin Gene-related Peptide Receptor Antagonist [EPC] | 2 | 0.0003 |
| 7 | Dipeptidyl Peptidase 4 Inhibitor [EPC] | 8 | 0.0002 |
| 8 | Survival of Motor Neuron 2 Splicing Modifier [EPC] | 1 | 0.0002 |
| 9 | Antiparasitic [EPC] | 1 | 0.0002 |